ERBB2 and cancer: Since T-DM1 is emerging as an important new line of therapy for metastatic HER2+ cancers, and depends on HER2 internalization for release of the cytotoxic payload emtansine [28], we next tested the role of Endo II in T-DM1 treatment response.